News

TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel ...
Stocktwits on MSN13h
Tuhura Biosciences Surges After-Hours As Investors Bet On Kineta Merger, Cancer Drug Pipeline
Shares of Tuhura Biosciences surged 20.2% in after-hours trading on Monday after the company and Kineta, Inc. said ...